Is Re-Shoring of APIs and FDFs (Finished Dosage Forms) to Europe Still Possible?

Is Re-Shoring of APIs and FDFs (Finished Dosage Forms) to Europe Still Possible? | During the worst weeks of the COVID-19, the patients, the Health Authorities and the public in general discovered the ugly truth: some of the most widely used drugs, such as paracetamol (a well-known painkiller), but also atracurium (a neuromuscular blocking drug required to facilitate endotracheal intubation) were no longer being produced in Europe. This effectively meant Europeans were relying on supplies from other countries, mainly located in South-East Asia. This realization prompted many promises by the Health Authorities on building a “European Strategic Healthcare Autonomy”. Unfortunately promises have not been fulfilled, the war in Ukraine, inflation, soaring energy costs… have contributed to shift focus and little progress has been made in re-shoring or bringing back API or finished medicines production to Europe. Is Europe still an attractive location for the pharma industry? Which measures could alleviate the dependency we have from other continents?